Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

NCT ID: NCT06770582Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-16

Summary

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.

Detailed description

PRIMARY OBJECTIVE: I. To compare bladder-intact event-free survival. SECONDARY OBJECTIVES: I. To assess complete response by cystoscopy at 6 months. II. To assess disease-free survival. III. To assess local-regional control. IV. To assess metastasis-free survival. V. To assess overall survival. VI. To assess quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Bladder Cancer Index at 18 months. VII. To assess Common Terminology Criteria for Adverse Events (CTCAE) adverse events (both acute and late). EXPLORATORY OBJECTIVES: I. To assess fatigue using the Patient Reported Outcomes Measurement Information System Fatigue-4A (PROMIS-Fatigue-4a). II. To assess quality adjusted survival using European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L). III. To assess cumulative quality of life using EORTC QLC-C30 and Bladder Cancer Index at 24 months. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive one of the following chemotherapy regimens per physicians choice: 1) cisplatin intravenously (IV) once per week for 4 weeks, 2) gemcitabine IV on days 1, 4, 8, 11, 15, 18, 22, and 25, or 3) mitomycin IV on day 1 and 5-fluorouracil IV continuously over 120 hours on days 1-5 and 16-20. Patients receiving cisplatin or gemcitabine continue chemotherapy for 6 weeks if they are receiving radiation according to the standard hypofractionated radiation schedule. Starting on day 1, patients also receive radiation therapy for 20, 32, or 36 treatments over 4-7 weeks. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT)/magnetic resonance imaging (MRI) and blood sample collection throughout the study. Patients may also undergo optional urine sample collection on study. ARM 2: Patients receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1, patients also receive radiation therapy for 20, 32, or 36 treatments over 4-7 weeks. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo CT/MRI and blood sample collection throughout the study. Patients may also undergo optional urine sample collection on study. After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years and then annually for 5 years.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

  • DrugCisplatin

    Given IV

  • ProcedureComputed Tomography

    Undergo CT

  • DrugFluorouracil

    Given IV

  • DrugGemcitabine

    Given IV

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • DrugMitomycin

    Given IV

  • BiologicalPembrolizumab

    Given IV

  • OtherQuestionnaire Administration

    Ancillary studies

  • RadiationRadiation Therapy

    Undergo radiation therapy

Outcome measures

Primary

  • Bladder intact event-free survival (BIEFS)

    Defined as time free of histologically proven recurrent T1-T4 recurrence, clinical evidence of nodal or distant metastasis, radical cystectomy (either for disease progression or due to toxicity), or death from any cause. Analysis will consist of estimation of the BIEFS curves via the Kaplan-Meier estimator and testing of the primary hypothesis using the stratified logrank test (one-sided). Additionally, the Cox proportional hazards model will be used to estimate the hazard ratio adjusting for stratification variables and any other baseline covariates that demonstrate any degree of imbalance by treatment arm.

    Time frame: Up to 5 years

  • Global quality of life

    Assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) global quality of life domain.

    Time frame: Up to 5 years

Secondary

  • Complete response by cystoscopy

    Time frame: At 6 months

  • Disease free survival

    Time frame: Up to 5 years

  • Local-regional control

    Time frame: Up to 5 years

  • Metastasis free survival

    Time frame: Up to 5 years

  • Overall survival

    Time frame: Up to 5 years

  • Quality of life

    Time frame: Up to 2 years

  • Incidence of adverse events (AE)

    Time frame: Up to 3 years

  • Bladder specific quality of life

    Time frame: Up to 2 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Pathologically (histologically) proven diagnosis of T1 high-grade non-muscle invasive urothelial carcinoma of the bladder without radiographic evidence of regional nodal disease or metastatic disease (N0, M0) on CT, MRI, or positron emission tomography (PET)/CT scan who would otherwise be treated with cystectomy off-trial. Patients should have cystectomy recommended disease but do not need to be medically operable for a cystectomy to be eligible for the trial. * NOTE: Patients with nodal disease ≥ 1 cm on short-axis or with suspicious nodes that are PET-avid of any size are not eligible * High grade T1 disease history that must meet at least ONE of the three criteria below: * Histologically confirmed recurrence with high-grade T1 urothelial carcinoma (+/- focal carcinoma in situ \[CIS\]) in the bladder following initial transurethral resection of bladder tumor (TURBT) and at least one induction course of intravesical therapy. Adequate induction course is defined as ≥ 5 doses of intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy when BCG is not available. * T1 with pathologic high-risk features (lymphovascular invasion \[LVI\] or variant histology of micropapillary, sarcomatoid, or plasmacytoid features) post initial TURBT. (No prior intravesical therapy required) * Persistent high-grade T1 urothelial carcinoma at repeat TURBT (+/- focal CIS) in the bladder. (No prior intravesical therapy required) * Restaging TURBT must be performed and must meet ALL of the following criteria below: * If there is absence of muscularis propria in the initial TURBT, there must be uninvolved muscularis propria in the restaging TURBT. * All grossly visible papillary tumors must be removed * Note: If the restaging TURBT is performed outside of the enrolling institution, an office cystoscopy should be performed by a Urologist who will be following the patient as part of the clinical trial * No pure squamous cell carcinoma or adenocarcinoma of the bladder * No neuroendocrine (small or large cell) features * No diffuse carcinoma in situ determined on cystoscopy and biopsy (i.e. extensive carcinoma in situ that is not just tumor-associated CIS in the opinion of the site investigator) * No prostatic urethral involvement * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy), tubal ligation or who is not postmenopausal * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3 * Platelets ≥ 100,000 cells/mm\^3 * Hemoglobin ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 9 g/dl is acceptable) * Adequate renal function defined as creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula, ≤ 1.5 × upper limit of normal (ULN) or creatinine levels \> 1.5 × institutional ULN * Total bilirubin ≤ institutional upper limit of normal (ULN) (Not applicable to patients with known Gilbert's syndrome) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 x institutional ULN * All adverse events of their most recent therapy/intervention must have resolved to \< grade 3 or returned to baseline prior to registration * No history of pelvic radiation therapy * No prior systemic chemotherapy or immunotherapy for urothelial carcinoma. Prior treatment with local intravesical therapy including BCG or chemotherapy is allowed * No prior treatment with anti-PD-1, anti PD-L1, anti PD-L2 or anti-CTLA4 antibody or any other antibody or drug targeting T-cell co-stimulation * No live vaccine administered within 30 days of registration. All non live vaccines (including the coronavirus disease \[COVID\] vaccine) are allowed at any time during the study. Timing should minimize confusion with drug-related toxicities where possible * Patients must have recovered from acute cardiac illness * New York Heart Association Functional Classification II or better (New York Heart Association \[NYHA\] Functional Classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) * No active infection requiring IV antibiotics * No active autoimmune disease that required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment * No history of idiopathic pulmonary fibrosis, organizing pneumonia, (non-infectious) pneumonitis that required steroids or current pneumonitis * No history of allogeneic bone marrow transplant or prior solid organ transplant * No active tuberculosis * No evidence of hydronephrosis * No history of upper tract urothelial carcinoma within 24 months of registration * No patients with a prior diagnosis of prostate cancer who have not received definitive treatment for their prostate cancer (e.g. on active surveillance) * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * No glucocorticoids except physiologic doses are allowed. The use of doses of corticosteroids (defined as 10 mg prednisone or equivalent) is acceptable * No history of allergic reaction to the drug excipients

Study locations (132)

Highlands Oncology Group - Fayetteville

Fayetteville, Arkansas, 72703

Recruiting
Site Public Contact · Contact
479-872-8100research@hogonc.com
Joseph T. Beck · Principal Investigator

Highlands Oncology Group - Rogers

Rogers, Arkansas, 72758

Recruiting
Site Public Contact · Contact
479-872-8130research@hogonc.com
Joseph T. Beck · Principal Investigator

Highlands Oncology Group

Springdale, Arkansas, 72762

Recruiting
Site Public Contact · Contact
479-872-8130research@hogonc.com
Joseph T. Beck · Principal Investigator

AIS Cancer Center at San Joaquin Community Hospital

Bakersfield, California, 93301

Recruiting
Site Public Contact · Contact
661-323-4673
Luis Mariscal · Principal Investigator

Los Angeles General Medical Center

Los Angeles, California, 90033

Recruiting
Site Public Contact · Contact
323-865-0451uscnorrisinfo@med.usc.edu
Lauren A. Lukas · Principal Investigator

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Recruiting
Site Public Contact · Contact
323-865-0451
Lauren A. Lukas · Principal Investigator

Shaw Cancer Center

Edwards, Colorado, 81632

Recruiting
Site Public Contact · Contact
970-569-7429
Erin Schwab · Principal Investigator

Helen F Graham Cancer Center

Newark, Delaware, 19713

Recruiting
Site Public Contact · Contact
302-623-4450lbarone@christianacare.org
Gregory A. Masters · Principal Investigator

Medical Oncology Hematology Consultants PA

Newark, Delaware, 19713

Recruiting
Site Public Contact · Contact
302-623-4450lbarone@christianacare.org
Gregory A. Masters · Principal Investigator

UF Health Cancer Institute - Gainesville

Gainesville, Florida, 32610

Recruiting
Site Public Contact · Contact
352-273-8010cancer-center@ufl.edu
Daniel V. Araujo · Principal Investigator

Mount Sinai Medical Center

Miami Beach, Florida, 33140

Recruiting
Site Public Contact · Contact
305-674-2625Yvonne.Enriquez@msmc.com
Bruno R. Bastos · Principal Investigator

Grady Health System

Atlanta, Georgia, 30303

Recruiting
Site Public Contact · Contact
404-778-1868
Kamran Salari · Principal Investigator

Emory Proton Therapy Center

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
404-251-2854allyson.anderson@emory.edu
Kamran Salari · Principal Investigator

Emory University Hospital Midtown

Atlanta, Georgia, 30308

Recruiting
Site Public Contact · Contact
888-946-7447
Kamran Salari · Principal Investigator

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Site Public Contact · Contact
404-778-1868
Kamran Salari · Principal Investigator

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342

Recruiting
Site Public Contact · Contact
404-851-7115
Kamran Salari · Principal Investigator

Rush MD Anderson Cancer Center

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Dian Wang · Principal Investigator

Carle at The Riverfront

Danville, Illinois, 61832

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Daniel H. Barnett · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Daniel H. Barnett · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Daniel H. Barnett · Principal Investigator

Carle BroMenn Medical Center

Normal, Illinois, 61761

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Daniel H. Barnett · Principal Investigator

Carle Cancer Institute Normal

Normal, Illinois, 61761

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Daniel H. Barnett · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Daniel H. Barnett · Principal Investigator

Mary Greeley Medical Center

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Ames

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-239-4734ksoder@mcfarlandclinic.com
Joseph J. Merchant · Principal Investigator

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Mercy Cancer Center-West Lakes

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-6727
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Broadlawns Medical Center

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-282-2200
Seema Harichand-Herdt · Principal Investigator

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

UI Healthcare Mission Cancer and Blood - Pella

Pella, Iowa, 50219

Recruiting
Site Public Contact · Contact
515-282-2921trials@missioncancer.com
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

The Iowa Clinic PC

West Des Moines, Iowa, 50266

Recruiting
Site Public Contact · Contact
515-875-9815
Seema Harichand-Herdt · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Eugene K. Lee · Principal Investigator

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Eugene K. Lee · Principal Investigator

University of Kansas Hospital-Indian Creek Campus

Overland Park, Kansas, 66211

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Eugene K. Lee · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Eugene K. Lee · Principal Investigator

Louisiana Hematology Oncology Associates LLC

Baton Rouge, Louisiana, 70809

Recruiting
Site Public Contact · Contact
225-215-1353clinicalresearch@marybird.com
Scott E. Delacroix · Principal Investigator

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, 70809

Recruiting
Site Public Contact · Contact
225-215-1353clinicalresearch@marybird.com
Scott E. Delacroix · Principal Investigator

Mary Bird Perkins Cancer Center - Gonzales

Gonzales, Louisiana, 70737

Recruiting
Site Public Contact · Contact
225-215-1353clinicalresearch@marybird.com
Scott E. Delacroix · Principal Investigator

Mary Bird Perkins Cancer Center - Metairie

Metairie, Louisiana, 70002

Recruiting
Site Public Contact · Contact
504-584-6990
Scott E. Delacroix · Principal Investigator

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114

Recruiting
Site Public Contact · Contact
877-726-5130
Sophia C. Kamran · Principal Investigator

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Trinity Health Medical Center - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
Site Public Contact · Contact
517-364-3712harsha.trivedi@umhsparrow.org
Samir Narayan · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Michigan Healthcare Professionals Pontiac

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
248-858-6215Emily.Crofts@trinity-health.org
Samir Narayan · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Samir Narayan · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Active Not Recruiting

Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Saint Mary's Medical Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Miller-Dwan Hospital

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Parkland Health Center - Farmington

Farmington, Missouri, 63640

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

University of Kansas Cancer Center - Briarcliff

Kansas City, Missouri, 64116

Recruiting
Site Public Contact · Contact
913-588-3671
Eugene K. Lee · Principal Investigator

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Eugene K. Lee · Principal Investigator

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Eugene K. Lee · Principal Investigator

Lake Regional Hospital

Osage Beach, Missouri, 65065

Recruiting
Site Public Contact · Contact
573-302-2768clinicaltrials@lakeregional.com
Jay W. Carlson · Principal Investigator

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
314-525-6042Danielle.Werle@mercy.net
Jay W. Carlson · Principal Investigator

Missouri Baptist Medical Center

St Louis, Missouri, 63131

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

BJC Outpatient Center at Sunset Hills

Sunset Hills, Missouri, 63127

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Justin M. Haseltine · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Mary E. Westerman · Principal Investigator

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Active Not Recruiting

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Active Not Recruiting

Riverside Methodist Hospital

Columbus, Ohio, 43214

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Michael Siedow · Principal Investigator

Grant Medical Center

Columbus, Ohio, 43215

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Michael Siedow · Principal Investigator

Doctors Hospital

Columbus, Ohio, 43228

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Michael Siedow · Principal Investigator

Dublin Methodist Hospital

Dublin, Ohio, 43016

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Michael Siedow · Principal Investigator

OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Michael Siedow · Principal Investigator

OhioHealth Marion General Hospital

Marion, Ohio, 43302

Recruiting
Site Public Contact · Contact
614-788-3860Jennifer.Sexton@ohiohealth.com
Michael Siedow · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Tyler Gunter · Principal Investigator

Christiana Care Health System-Concord Health Center

Chadds Ford, Pennsylvania, 19317

Recruiting
Site Public Contact · Contact
302-623-4450lbarone@christianacare.org
Gregory A. Masters · Principal Investigator

Geisinger Medical Center

Danville, Pennsylvania, 17822

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Heath B. Mackley · Principal Investigator

Geisinger Cancer Center Dickson City

Dickson City, Pennsylvania, 18519

Recruiting
Site Public Contact · Contact
877-204-6081hemoncctrials@geisinger.edu
Heath B. Mackley · Principal Investigator

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Adam Olson · Principal Investigator

UPMC Cancer Center at UPMC Horizon

Farrell, Pennsylvania, 16121

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Adam Olson · Principal Investigator

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601

Recruiting
Site Public Contact · Contact
724-838-1900
Adam Olson · Principal Investigator

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033-0850

Recruiting
Site Public Contact · Contact
717-531-3779CTO@hmc.psu.edu
Hyma Polimera · Principal Investigator

Geisinger Medical Oncology-Lewisburg

Lewisburg, Pennsylvania, 17837

Recruiting
Site Public Contact · Contact
570-374-8555HemonCCTrials@geisinger.edu
Heath B. Mackley · Principal Investigator

UPMC Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Adam Olson · Principal Investigator

UPMC Hillman Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146

Recruiting
Site Public Contact · Contact
412-864-7716ClinicalResearchServices@upmc.edu
Adam Olson · Principal Investigator

UPMC Hillman Cancer Center - New Castle

New Castle, Pennsylvania, 16105

Recruiting
Site Public Contact · Contact
412-389-5208haneydl@upmc.edu
Adam Olson · Principal Investigator

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213

Recruiting
Site Public Contact · Contact
412-647-2811
Adam Olson · Principal Investigator

UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215

Recruiting
Site Public Contact · Contact
412-784-4900
Adam Olson · Principal Investigator

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-647-8073
Adam Olson · Principal Investigator

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232

Recruiting
Site Public Contact · Contact
412-621-2334
Adam Olson · Principal Investigator

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237

Recruiting
Site Public Contact · Contact
412-367-6454
Adam Olson · Principal Investigator

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, 16346

Recruiting
Site Public Contact · Contact
814-676-7900
Adam Olson · Principal Investigator

UPMC Cancer Center-Washington

Washington, Pennsylvania, 15301

Recruiting
Site Public Contact · Contact
412-339-5294Roster@nrgoncology.org
Adam Olson · Principal Investigator

UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, 15301

Recruiting
Site Public Contact · Contact
724-223-3788cancer@washingtonhospital.org
Adam Olson · Principal Investigator

Geisinger Wyoming Valley/Henry Cancer Center

Wilkes-Barre, Pennsylvania, 18711

Recruiting
Site Public Contact · Contact
570-271-5251HemonCCTrials@geisinger.edu
Heath B. Mackley · Principal Investigator

Central Vermont Medical Center/National Life Cancer Treatment

Berlin Corners, Vermont, 05602

Recruiting
Site Public Contact · Contact
802-225-5400
Alexander P. Lukez · Principal Investigator

University of Vermont Medical Center

Burlington, Vermont, 05401

Recruiting
Site Public Contact · Contact
802-656-4101rpo@uvm.edu
Alexander P. Lukez · Principal Investigator

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

Recruiting
Site Public Contact · Contact
802-656-8990rpo@uvm.edu
Alexander P. Lukez · Principal Investigator

University of Virginia Cancer Center

Charlottesville, Virginia, 22908

Recruiting
Site Public Contact · Contact
434-243-6303uvacancertrials@hscmail.mcc.virginia.edu
Christopher Luminais · Principal Investigator

Bon Secours Memorial Regional Medical Center

Mechanicsville, Virginia, 23116

Recruiting
Site Public Contact · Contact
804-893-8978anne_carmellat@bshsi.org
Joseph D. Pennington · Principal Investigator

Bon Secours Saint Francis Medical Center

Midlothian, Virginia, 23114

Recruiting
Site Public Contact · Contact
804-893-8978anne_carmellat@bshsi.org
Joseph D. Pennington · Principal Investigator

Bon Secours Saint Mary's Hospital

Richmond, Virginia, 23226

Recruiting
Site Public Contact · Contact
804-893-8978anne_carmellat@bshsi.org
Joseph D. Pennington · Principal Investigator

Bon Secours Cancer Institute at Reynolds Crossing

Richmond, Virginia, 23230

Recruiting
Site Public Contact · Contact
804-893-8978Anne_caramella@bshsi.org
Joseph D. Pennington · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Alfredo I. Urdaneta · Principal Investigator

VCU Community Memorial Health Center

South Hill, Virginia, 23970

Recruiting
Site Public Contact · Contact
nemer.elmouallem@vcuhealth.org
Alfredo I. Urdaneta · Principal Investigator

West Virginia University Healthcare

Morgantown, West Virginia, 26506

Recruiting
Site Public Contact · Contact
304-293-7374cancertrialsinfo@hsc.wvu.edu
Joanna A. Kolodney · Principal Investigator

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Northwest Wisconsin Cancer Center

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Bevan Ly · Principal Investigator